Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Philogen SpA ( (IT:PHIL) ) just unveiled an announcement.
Philogen S.p.A. has reported a positive net financial position of 369,164 thousand euros for the third quarter of 2025, marking a significant increase from the previous quarter. The company is advancing its clinical trials for Nidlegy™ and Fibromun, with new studies initiated for basal cell carcinoma and squamous cell carcinoma. The company is also preparing to launch a Phase III clinical study for 68Ga-OncoCAIX imaging and planning further Phase I studies, highlighting its strong financial base and commitment to expanding its product development pipeline.
The most recent analyst rating on (IT:PHIL) stock is a Buy with a EUR26.00 price target. To see the full list of analyst forecasts on Philogen SpA stock, see the IT:PHIL Stock Forecast page.
More about Philogen SpA
Philogen S.p.A. is a biotechnology company focused on the development of innovative biopharmaceutical products, particularly in the field of oncology. The company is involved in the development of therapeutic and diagnostic products, with a market focus on skin tumors, including melanoma and non-melanoma skin cancers.
Average Trading Volume: 21,628
Technical Sentiment Signal: Buy
Current Market Cap: €696M
Learn more about PHIL stock on TipRanks’ Stock Analysis page.